NPPA examining 92 applications to fix price of new FDCs

Also, last month, the Health Ministry had banned 344 FDCs through a gazette notification issued over the weekend

National Pharmaceutical Pricing Authority (NPPA) is currently evaluating 92 applications for retail price fixation of new fixed dose combinations (FDCs), Parliament was informed on Friday.

Besides, the NPPA has directed all pharmaceutical companies whose applications for retail price fixation of new FDCs are pending to submit a declaration signed by the designated authority that the FDC has not been banned by drug control authorities.

"At present, 92 applications for retail price fixation of new FDCs are under examination at NPPA," Minister of State for Chemicals and Fertilisers Hansraj Gangaram Ahir said in a written reply to the Rajya Sabha.

Read more from our special coverage on "NPPA"

• NPPA caps prices of 70 new drugs

Ceiling and retail prices are fixed only for those formulations, including FDCs, which have valid approvals from the Drug Control Authority.

Last month, the Health Ministry had banned 344 FDCs through a gazette notification issued over the weekend.

Various drug firms which were impacted by the ban later approached the court.